The Pediatric Solid Tumor Program at UF Health treats children, adolescents, and young adults with a variety of solid malignancies, from bone and soft-tissue sarcomas to liver, adrenal, kidney, and other rare tumors. Our team will provide your child with a comprehensive treatment plan that is specific to his/her tumor type. In addition to the individual attention your child will receive from your primary oncologist, your child will benefit from the collective expertise of the entire solid tumor treatment group. Housed within our program are other services including Adolescent and Young Adult (AYA) Cancer, Vascular Anomaly and Cancer Predisposition programs.
Our team includes the following members:
- A dedicated pediatric solid tumor team who are well-versed in the most recent treatment innovations in this field
- Expert orthopedic oncologists, pediatric surgeons and interventional radiologists with extensive experience in surgical and procedural treatments of childhood and AYA cancers and vascular anomalies
- Radiation oncologists with access to leading-edge technology, including proton radiation therapy
- Expert pathologists who use molecular diagnostic testing to identify the tumor type
- A Quality of Life Program team who focuses on supportive measures that will help your child and family live the best lives possible, despite the diagnosis of a life-limiting or life-threatening disease.
- Reproductive fertility experts who provide options for fertility preservation before starting treatment
- We also draw on the expertise of a variety of support staff, including nurses, clinical pharmacists, social workers, nutritionists, physical therapists, occupational therapists, and child life specialists.
Dr. Joanne Lagmay, Director of the Pediatric Solid Tumor Program, collaborates with members of the Veterinary Medicine, Engineering, Chemistry, Materials Science, and Radiation Oncology in the development of polymer‐mediated radionuclide therapies in an osteosarcoma canine model. She is also collaborating with Elias Sayour, M.D., Ph.D. and John Ligon M.D. in the NIH RO1 funded immunotherapy laboratory at UF in developing an early phase trial for recurrent pediatric solid tumors.
Through local and national partnerships, the Pediatric Solid Tumor Program has been successful in enrolling patients in novel clinical trials. Such participation in clinical research efforts allows us to provide patients and families with access to both expert, state-of-the-art care, as well as clinical trial options.